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erythematosusAbstract Background: Malondialdehyde (MDA) is a marker of oxidative stress (OS) and one of
the major alternative complement pathway (ACP) activators associated with systemic lupus erythe-
matosus (SLE) activity. ACP is the principal mediator of SLE inflammation and progression.
Aim of the work: To investigate the association between the ACP functional activity and plasma
MDA in SLE patients.
Patients and methods: Sixteen consecutive SLE patients were analyzed for their complement pro-
file and oxidative stress measurement. 60 healthy subjects were included as a control group. The
Complement components C3, C4 and properdin-factor B (PfB) were assessed, ACP activity was
assayed according to alternative hemolytic 50 (AH50). Plasma total lipid peroxide quantification
was performed by assessing the plasma MDA. Total antioxidant capacity was measured with oxy-
gen radical absorbance capacity (ORAC). OS ratio was calculated by dividing the total antioxidant
capacity by MDA.
Results: Sixteen patients (13 females and 3 males) with a mean age of 27.86 ± 6.26 years and a
disease duration 69.65 ± 54.65 months were included. There was a significant increase of MDA in
the patients (MFI = 613 ± 56.21) compared to the control (MFI = 460 ± 37.85) (p= 0.003). C3
was significantly consumed and MDA increased in the low AH50 compared to the normal AH50
patients (p= 0.02 and p= 0.01 respectively). AH50 significantly negatively correlated with the
C3 (p= 0.02) and MDA (p= 0.048). There was lack of any association between ORAC and
ACP. Properdin factor B significantly negatively correlated with C3 (p= 0.007).
Conclusions: These initial results encourage future in-depth studies on the association of
OS–ACP in SLE pathogenesis.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1 Characteristics of the active and inactive SLE
patients.
Characteristic mean ± SD
or n (%)
SLE patients (n= 16)
Inactive (n= 5) Active (n= 11)
Age (years) 31.67 ± 7.2 24.1 ± 5.3
Disease duration (months) 95.3 ± 59.1 44 ± 50.2
SLEDAI – 10 ± 2.3
ANA positivity 5 (100) 10
Prednisone intake 3 (60) 11
Chloroquine intake 4 (80) 9
SLEDAI: systemic lupus erythematosus disease activity index,
ANA: antinuclear antibodies.
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Systemic lupus erythematosus (SLE) is a multisystem autoim-
mune disorder characterized by microvascular inflammation
and development of autoantibodies [1]. The exact cause of
SLE is unknown; multiple factors including genetic and envi-
ronmental [2] and various key players as cytokines [3,4] oxida-
tive stress [5] and apoptosis [6] are implicated in the
pathogenesis of the disease. Dysfunction of the T lymphocytes,
B lymphocytes and dendritic cells, production of antinuclear
autoantibodies and the loss of self-tolerance reveal the defec-
tive immune regulatory mechanisms [7] and increased oxida-
tive damage [8,9].
The past decade has known intensive research efforts con-
cerning the two major damage factors in SLE: oxidative stress
(OS) and the alternative complement pathway (ACP) [10,11].
Complement was found to bind to malondialdehyde (MDA)
epitopes and protects from oxidative stress [12]. Complement
plays a dual role in the progression of SLE since it has impor-
tant protective functions, such as the clearance of immune
complexes and apoptotic cells, but is also a mediator of renal
inflammation. However, selectively inhibiting the ACP is ben-
eficial, presumably because of protective contributions from
the classical and/or lectin pathways [13].
Oxidative stress contributes to immunomodulation which
may lead to autoimmune diseases as SLE, antiphospholipid
syndrome, rheumatoid arthritis (RA) [14–16], scleroderma
[17] and Behcet’s disease [18]. Reactive oxygen species are
implicated in SLE and oxidative stress has the potential to eli-
cit an autoimmune response, to contribute to the pathogenesis
and could be useful when determining a prognosis [19]. Oxida-
tive imbalance with an increase in MDA and a decrease in
antioxidants plays a pathogenic role in the progression of
SLE disease [20,21] and a possible cause of disease activity
[22]. Inhibition of oxidative stress may represent newly discov-
ered molecular and cellular targets for the treatment of SLE
[7]. Antioxidants may protect against development of RA or
SLE by combating oxidative stress [23,24].
Oxidative stress plays an important role in many aging dis-
eases, including cardiovascular disease and age-related macu-
lar degeneration (AMD). Complement factor H risk allele
confers higher complement activation and cell lysis activity
in AMD by modulating oxidative stress and interacting with
oxidized phospholipids [25]. However, these two lesional fac-
tors have not been analyzed simultaneously in this SLE.
The current study aimed to describe some evidence for OS–
ACP association with a hope to initiate further studies to fill
this gap in such a complex inflammatory disorder.
2. Patients and methods
This pilot study involved 16 consecutive SLE patients attend-
ing different wards of the Military University Hospital of
Oran, Algeria fulfilling the 1997 American college of Rheuma-
tology criteria [26]. Sixty healthy subjects (30 females and 30
males) of matched age served as a control. The study protocol
was fully approved by the ethics committee of the Regional
Military University Hospital of Oran (Oran, Algeria). All
patients gave written informed consent. Other diseases such
as diabetes mellitus, rheumatoid arthritis and antiphospholipid
syndrome that may cause oxidative stress were excluded.The plasma was separated and stored at 80 C until anal-
ysis. The Complement components C3, C4 and properdin-
factor B (PfB) were assessed in all samples by nephelometry
laser (Image 800, Beckman Coulter, USA). ACP activity was
assayed according to previously described method AH50 [27].
Plasma total lipid peroxide quantification was performed by
malondialdehyde (MDA) level measurement using thiobarbi-
turic acid reactive substance (TBARS) method and the results
were given as mean fluorescence intensity (MFI) [28,29]. Total
antioxidant capacity was measured with oxygen radical absor-
bance capacity (ORAC) with a 1:150 plasma dilution. The
results were given as area under curve (AUC) [30]. OS ratio
was calculated by dividing the total antioxidant capacity by
MDA [31].
Statistical analysis was done by using SPSS (IBM software
version 20.0 Chicago-USA). Student’s t-test was performed for
means comparison. In order to investigate whether or not OS
parameters and plasma ACP activity were correlated, two
tailed Pearson correlation was carried out. Significance was
defined as p 6 0.05.
3. Results
Sixteen patients (13 females and 3 males) with a mean age of
27.86 ± 6.26 years and a disease duration of 69.65
± 54.65 months were included. The antinuclear antibody
(ANA) positivity, disease activity and medications received
of the active and inactive SLE patients are presented in Table 1.
The 60 control (30 females and 30 males) had a mean age of
27.88 ± 8.28 years.
There was a significant increase of MDA in the patients
(MFI = 613 ± 56.21) compared to the control (MFI = 460
± 37.85) (p= 0.003). When SLE patients were divided into
two groups according to their ACP activity AH50 (<80%
and P80%), both groups showed higher plasma MDA
adducts than controls, but the levels were much greater in
the low AH50 group. Interestingly, only C3 and MDA changed
when the ACP was consumed (Table 2). The lack of any asso-
ciation between antioxidant defense capacity (ORAC) and
ACP (Table 3) was unexpected.
The MDA level significantly correlated with AH50, indicat-
ing that increased complement ACP activity parallels with
lipid peroxidation endproduct levels (Table 3). Furthermore,
the estimation curve by linear regression shows that MDA
may explain ACP function by nearly 26% (R2 = 0.27,
p= 0.048) (Fig. 1).
Table 2 Complement factors and oxidative balance according
to the alternative complement pathway activity in SLE
patients.
Mean ± SD SLE patients (n= 16)
AH50 N (n= 5) AH50 low (n= 11) p
PfB (mg/dl) 54.4 ± 13 18.1 ± 14.5 0.42
C3 (mg/dl) 93.7 ± 7.8 59.76 ± 7.9 0.02*
C4 (mg/dl) 8.1 ± 1.4 8.87 ± 0.5 0.54
ORAC (AUC) 8.7 ± 0.08 8.49 ± 0.11 0.21
MDA (MFI) 532.2 ± 40.3 666.8 ± 60.2 0.01*
OS ratio 1.7 ± 0.1 1.3 ± 0.1 0.05
AH50: alternative hemolytic 50, N: normal activity (P80%), PfB:
Properdin factor B, C: complement, ORAC: antioxidant defense
capacity, MDA: malondialdehyde, OS: oxidative stress, AUC: area
under curve.
* Significantly different at p< 0.05.
Table 3 Correlations among oxidative stress and complement
parameters in SLE patients.
Parameter r(p) SLE patients (n= 16)
AH50
PfB 0.32 (0.36)
C3 0.58 (0.02)*
C4 0.06 (0.83)
MDA 0.52 (0.048)*
ORAC 0.17 (0.56)
Properin factor B
C3 0.79 (0.007)**
C4 0.62 (0.05)
MDA 0.03 (0.94)
ORAC 0.08 (0.82)
Malondialdehyde
C3 0.29 (0.29)
C4 0.29 (0.29)
AH50: alternative hemolytic 50, PfB: Properdin factor B, C: com-
plement, MDA: malondialdehyde, ORAC: antioxidant defense
capacity, * = significant at p< 0.05 and ** at p< 0.01.
Figure 1 Correlation between the alternative complement path-
way activity as expressed by the alternative hemolytic 50 (AH50)
with malondialdehyde (MDA) in SLE patients.
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The present study shows that plasma MDA levels and ACP
activity were still found to be very high which concords with
previous studies [10,32–34]. At present, it is widely accepted
that both ACP and MDA are the major mediators of tissue
inflammation and SLE progression; On one hand, MDA is
associated with disease activity [11]; and on the other hand,
ACP represents 80% of complement activity and, is considered
as the sole complement pathway involved in SLE tissue
damage [13,35].
Importantly, the current study showed that ACP activity
significantly correlated with MDA levels which are not in
contrast to the evidence that MDA is one of the potent ACP
activators. On linear regression 26.8% of ACP activity in
SLE may be explained by the increased plasma MDA level
as a dependant variable. Of note, it is known that early SLE
pathogenesis implicates OS [36] but we wondered if therewas an interesting association with ACP, as described in
AMD pathogenesis [12]. Prompted by previous reports about
MDA regulation by factor H (FH) in AMD affected eyes,
we inferred that OS:ACP interaction might play a key role in
SLE pathogenesis. Needless to remind that as the pillar of
the immune surveillance, the complement system attacks
everything that is not specifically protected. This action is pro-
vided by ACP, which is permanently active and constantly
probes the environment for the presence of activating surfaces.
In OS-related pathologies, oxidized biomolecules and their
breakdown products like MDA are generated and, if not prop-
erly handled by FH, they activate the ACP [12,25]. Besides,
this pathway is characterized by the so-called ‘‘amplification
loop” that decreases deeply plasma C3 level. Therefore, the
data obtained in our study showing that only C3 and MDA
correlate with ACP activity is explained by the aforesaid
concepts.
Such results would have a particular relevance to current
therapeutic approaches and clinical trials based upon antioxi-
dant treatment [37]. Nonetheless, our observations raise ques-
tions concerning the long-term use of rituximab, the anti CD20
monoclonal antibody, as a treatment for SLE disease since this
therapy is associated with high reactive oxygen species (ROS)
generation [38].
As far as we know, this preliminary result is the first report
of an eventual association between ACP and MDA in SLE.
These findings merit further investigation with larger studies
in order to understand exactly the role of OS:ACP interaction
on the disease progress, manifestations, activity and outcome
in a purpose to develop novel disease preventive biomarkers.
Among the limitations of this pilot study is the lack of analysis
of clinical manifestations, medications received, disease activ-
ity and damage which could be taken into consideration in
future studies.
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